We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-19.62%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$966M
AUM Growth
-$102M
Cap. Flow
+$140M
Cap. Flow %
14.53%
Top 10 Hldgs %
64.34%
Holding
33
New
2
Increased
11
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$64.4M
2
BLUE
bluebird bio
BLUE
+$28.3M
3
CDNA icon
CareDx
CDNA
+$22.2M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.2M
5
FULC icon
Fulcrum Therapeutics
FULC
+$9.34M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.04M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.96M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$3.58M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$2.15M
5
EDIT icon
Editas Medicine
EDIT
+$1.61M

Sector Composition

Rank Sector Weight
1 Healthcare 81.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
26
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$9.84M 1.02%
1,523,960
– –
EDIT icon
27
Editas Medicine
EDIT
$407M
$9.44M 0.98%
415,000
-65,000
-14% -$1.61M
TWST icon
28
Twist Bioscience
TWST
$6.29B
$7.16M 0.74%
300,000
– –
FULC icon
29
Fulcrum Therapeutics
FULC
$283M
$5.61M 0.58%
+844,285
New +$9.34M
ORTX
30
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.68M 0.38%
31,000
+21,000
+210% +$2.93M
DCPH
31
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.39M 0.35%
+100,000
New +$2.96M
TPTX
32
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.82M 0.29%
75,000
+15,000
+25% +$653K
STOK icon
33
Stoke Therapeutics
STOK
$1.84B
$2.79M 0.29%
130,000
+45,000
+53% +$1.25M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Casdin Capital held 33 positions worth $966M, down 9.6% from $1.07B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Casdin Capital deployed $140M of net new capital in Q3 2019, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was Fulcrum Therapeutics: 844,285 shares worth $5.61M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $9.04M trimmed.

  • Casdin Capital's largest Q3 2019 buy was Fulcrum Therapeutics: 844,285 shares worth $5.61M.
  • Casdin Capital added most to Sarepta Therapeutics in Q3 2019, an estimated $64.4M increase.
  • Casdin Capital's biggest Q3 2019 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $9.04M.
  • Casdin Capital's ten largest holdings make up 64% of its $966M portfolio in Q3 2019.
  • Casdin Capital opened 2 new positions and closed 0 in Q3 2019.
  • Casdin Capital's portfolio value fell 9.6% quarter-over-quarter to $966M.

Based on Casdin Capital's 13F filing for Q3 2019, filed 12 Nov 2019.